Redefining Pulmonary Arterial Hypertension Treatment: Sotatercept's FDA Priority Review
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
A biologics license application (BLA) for sotatercept, a therapeutic agent targeting activin receptor signaling implicated in pulmonary arterial hypertension (PAH), has been granted priority review status by the FDA. This advancement underscores the critical need for novel pharmacological interventions for this rare and severe condition, potentially transforming the therapeutic landscape of PAH.
References
1.
Raftopoulos H, Laadem A, Hesketh P, Goldschmidt J, Gabrail N, Osborne C
. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2015; 24(4):1517-25.
PMC: 4766217.
DOI: 10.1007/s00520-015-2929-9.
View
2.
Hoeper M, Badesch D, Ghofrani H, Gibbs J, Gomberg-Maitland M, McLaughlin V
. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023; 388(16):1478-1490.
DOI: 10.1056/NEJMoa2213558.
View
3.
Souza R, Badesch D, Ghofrani H, Gibbs J, Gomberg-Maitland M, McLaughlin V
. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial. Eur Respir J. 2023; 62(3).
PMC: 10512088.
DOI: 10.1183/13993003.01107-2023.
View
4.
McLaughlin V, Alsumali A, Liu R, Klok R, Martinez E, Nourhussein I
. Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH). Adv Ther. 2023; 41(1):130-151.
PMC: 10796519.
DOI: 10.1007/s12325-023-02684-x.
View